医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Kaneka Releases PCR Test Kit for COVID-19 Variants

2021年10月11日 AM09:00
このエントリーをはてなブックマークに追加


 

TOKYO

Kaneka Corporation (TOKYO:4118) has released KANEKA RT-PCR Kit SARS-CoV-2 (L452R/E484Q/E484K/N501Y), a real-time PCR test kit capable of simultaneously detecting four variants of COVID-19. The new kit has a suggested retail price of 217,800 yen, including tax, and is available for purchase starting from September 30.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211010005005/en/

KANEKA RT-PCR Kit SARS-CoV-2 (L452R/E484Q/E484K/N501Y) (Photo: Business Wire)

KANEKA RT-PCR Kit SARS-CoV-2 (L452R/E484Q/E484K/N501Y) (Photo: Business Wire)

This test kit uses a reagent developed using Kaneka’s molecular testing-related technologies. The reagent makes it possible to simultaneously detect four mutations*1 of spike protein (the N501Y, E484K, E484Q, and L452R mutations) with a single PCR test. Based on the mutation detection patterns, it can efficiently detect*2 variants (the Alpha, Delta, Kappa, and Beta or Gamma variants).

The PCR kit for detecting COVID-19 released by Kaneka last year received approval in June of this year as “KANEKA Direct RT-PCR kit SARS-CoV-2″ for use as an In-Vitro Diagnostic reagent. It is widely used in medical facilities and testing centers. By adding this new COVID-19 variant PCR test kit to our lineup, we are contributing to the rapid detection of variants and the prevention of the spread of COVID-19.

Kaneka is taking a wide range of measures to combat COVID-19. These include the launching of the “Infection Initiative Team,” which conducts research and development regarding infection control measures including COVID-19, performing contract manufacturing of DNA vaccine APIs and intermediates, supplying the API used in “AviganTM”, developing antibody drugs, supplying PCR testing reagents and testing kits, and shipping vaccine using temperature controlled packages.

*1. These refer to mutations of the amino acids in viral spike proteins. The names are based on the mutation. In the N501Y mutation, the 501st amino acid in the spike protein has changed from N (asparagine) to Y (tyrosine). In the E484K mutation, the change was from E (glutamine acid) to K (lysine). In E484Q, it was from E (glutamine acid) to Q (glutamine). In L452R, it was from L (leucine) to R (arginine).

*2. Relationship between detected COVID-19 mutations and variants (+: positive, -: negative)
This product cannot distinguish Beta variants from Gamma variants.

N501Y

E484K

E484Q

L452R

Determination

+

==>

Alpha variant

+

==>

Delta variant

+

+

==>

Kappa variant

+

+

==>

Beta or Gamma variant

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211010005005/en/

CONTACT

KANEKA CORPORATION

Medical Solutions Vehicle

Takaaki Jikihara

https://www.kaneka-labtest.com/en/contact-us.html

kaneka_ivd_team@kaneka.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • デックスレボ、IMCAS 2023でGOURIがテーマのシンポジウムとブランドイベントを開催
  • Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology
  • Herbalife Nutrition’s Expertise and Leadership in Nutrition Will Be Featured at Upcoming Global Scientific and Wellness Conferences in the First Quarter
  • エクセンシア、ブリストル マイヤーズ スクイブにライセンスしたPKCシータ阻害剤EXS4318のヒト初回投与試験の開始を発表
  • Dentalis Animal Health任命顾问委员会